News

September 21, 2018September 21, 2018

FDA Approves Subcutaneous Form of Actemra for Active Systemic Juvenile Idiopathic Arthritis

News

The U.S. Food and Drug Administration (FDA) has approved Genentech’s formulation of Actemra (tocilizumab) by subcutaneous injection for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 and ... Read more

September 10, 2018September 10, 2018

Actemra Shows Sustained Safety, Efficacy in Children with pJIA, Extension Trial Shows

News

Long-term treatment with Actemra (tocilizumab) shows sustained safety and effectiveness in children with polyarticular juvenile idiopathic arthritis (pJIA), according to the results of a Phase 3 clinical trial. The ... Read more

September 7, 2018September 7, 2018

Humira’s Safety in Children With JA, Other Diseases Comparable to That in Adults, Study Suggests

News

The safety profile of Humira (adalimumab) in children with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, and Crohn’s disease is similar to that in adults, a large analysis of ... Read more

August 31, 2018August 31, 2018

Terry Bradshaw Supports ACR’s ‘Simple Tasks’ Initiative for Rheumatic Disease Care

News

In a nationwide public service announcement, former Pittsburgh Steelers quarterback Terry Bradshaw urges fellow rheumatic disease patients to take the pledge to manage their disease and live well. The ... Read more

August 24, 2018August 24, 2018

Actemra, Kineret Have Similar One-Year Efficacy in sJIA Patients, Study Finds

News

Treatment of systemic juvenile idiopathic arthritis (sJIA) with either the approved therapy Actemra (tocilizumab) or Kineret (anakinra, not yet approved for sJIA) led to similar effectiveness after one year, according to a ... Read more

August 20, 2018August 20, 2018

Early Decrease in Inflammatory Molecule IL-6 is Predictor of Clinical Remission, Study Shows

News

An early reduction in levels of the inflammatory molecule IL-6 is significantly associated with clinical remission at two years after diagnosis in patients with systemic juvenile idiopathic arthritis, a ... Read more

August 6, 2018August 6, 2018

Naproxen-based Combo May Help Reduce Risk of Gastric Ulcers in JIA Teens, Phase 4 Trial Shows

News

Results from a six-month, Phase 4 trial support a combination therapy of the anti-inflammatory naproxen together with an immediate-release form of esomeprazole to reduce the risk of gastric ulcers ... Read more

July 30, 2018July 30, 2018

Orofacial Pain Fairly Common – and Disabling – in Children, Study Reports

News

Orofacial pain — continuous discomfort in the mouth, jaws, and face — can be fairly common and persistent in children with juvenile idiopathic arthritis (JIA), and sufficiently limiting to ... Read more

July 23, 2018July 23, 2018

Low Number of Regulatory B-cells May Help Fuel Juvenile Idiopathic Arthritis, Study Suggests

News

Low numbers of a group of immune cells — called regulatory B-cells — that help to control inflammation may underlie the development of juvenile idiopathic arthritis (JIA), early research ... Read more

July 16, 2018July 16, 2018

Kineret Now Available in UK for Systemic-onset JIA and Still’s Disease

News

Kineret (anakinra), developed by Sobi, is now available as a treatment option in the United Kingdom for patients with systemic-onset juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD). ... Read more

Pin It on Pinterest